ATE189682T1 - Prohormonspaltungsplatzblockierungsantikörper - Google Patents

Prohormonspaltungsplatzblockierungsantikörper

Info

Publication number
ATE189682T1
ATE189682T1 AT90913016T AT90913016T ATE189682T1 AT E189682 T1 ATE189682 T1 AT E189682T1 AT 90913016 T AT90913016 T AT 90913016T AT 90913016 T AT90913016 T AT 90913016T AT E189682 T1 ATE189682 T1 AT E189682T1
Authority
AT
Austria
Prior art keywords
prohormone
blocking antibodies
place blocking
cleavage place
prohormone cleavage
Prior art date
Application number
AT90913016T
Other languages
English (en)
Inventor
Michael Kriegler
Carl Perez
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE189682T1 publication Critical patent/ATE189682T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT90913016T 1989-08-16 1990-08-13 Prohormonspaltungsplatzblockierungsantikörper ATE189682T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39525489A 1989-08-16 1989-08-16
PCT/US1990/004536 WO1991002756A1 (en) 1989-08-16 1990-08-13 Prohormone cleavage site blocking antibody

Publications (1)

Publication Number Publication Date
ATE189682T1 true ATE189682T1 (de) 2000-02-15

Family

ID=23562288

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90913016T ATE189682T1 (de) 1989-08-16 1990-08-13 Prohormonspaltungsplatzblockierungsantikörper

Country Status (8)

Country Link
US (3) US5677182A (de)
EP (1) EP0487610B1 (de)
JP (1) JPH05501351A (de)
AT (1) ATE189682T1 (de)
AU (1) AU641178B2 (de)
CA (1) CA2023250A1 (de)
DE (1) DE69033457T2 (de)
WO (1) WO1991002756A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0614984B2 (de) * 1993-03-05 2010-11-03 Bayer HealthCare LLC Humane monoklonale anti-TNF alpha Antikörper
EP0657469A1 (de) * 1993-10-26 1995-06-14 Boehringer Ingelheim Pharmaceuticals Inc. L-Selektinspaltungsplatz, Verfahren zur Diagnose une ihre Verwendung
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
ATE274346T1 (de) * 1995-06-08 2004-09-15 Immunex Corp Tnf-alpha konvertierendes enzym
US5830742A (en) * 1995-06-08 1998-11-03 Immunex Corporation TNF-α converting enzyme
IL114461A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev TNF modulation
CN1310675C (zh) * 1995-07-20 2007-04-18 依默耐克斯有限公司 TNF－α转变酶
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
ATE472556T1 (de) 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
JP4769456B2 (ja) * 2004-12-27 2011-09-07 昭和シェル石油株式会社 ウレア系潤滑グリース組成物、転がり軸受けおよび電動パワーステアリング装置
NZ580530A (en) 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
CA2751311C (en) 2009-02-19 2019-08-06 Merz Pharma Gmbh & Co. Kgaa Means and methods for manufacturing highly pure neurotoxin
CA2757637C (en) * 2009-04-27 2017-10-24 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JP2647427B2 (ja) * 1987-04-24 1997-08-27 帝人株式会社 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット
NZ229922A (en) * 1988-07-18 1992-04-28 Chiron Corp Monoclonal antibodies specifically binding cachectin (tumor necrosis factor) and compositions
JP3443119B2 (ja) * 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド

Also Published As

Publication number Publication date
WO1991002756A1 (en) 1991-03-07
DE69033457D1 (en) 2000-03-16
US5686259A (en) 1997-11-11
EP0487610B1 (de) 2000-02-09
JPH05501351A (ja) 1993-03-18
AU6276590A (en) 1991-04-03
US5702705A (en) 1997-12-30
DE69033457T2 (de) 2000-09-14
CA2023250A1 (en) 1991-02-16
US5677182A (en) 1997-10-14
EP0487610A1 (de) 1992-06-03
AU641178B2 (en) 1993-09-16

Similar Documents

Publication Publication Date Title
DE69033457D1 (en) Prohormonspaltungsplatzblockierungsantikörper
NO985150D0 (no) Antigenbindende fragment som sµrlig sporer kreftceller, nukleoid som koder nevnte fragment, samt bruk av dette ved forebygging og pÕvisning av kreft
NO942850D0 (de)
EP0701571A1 (de) Antikoerperfragmente in therapie
ATE267610T1 (de) Glykosylierte igg antikörper
EP1097945A3 (de) Für menschlichen Tumornekrose-Faktor spezifische monoklonale und chimäre Antikörper
Lin et al. Three pregnancy-associated human plasma proteins: purification, monospecific antisera and immunological identification
BRPI0410129B8 (pt) anticorpo anti-cs1 isolado, fragmento de ligação de antígeno, composto conjugado e composição farmacêutica
RU2008128244A (ru) Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2
AU3327701A (en) Humanized anti-ccr2 antibodies and methods of use therefor
NO913211L (no) Nytt monoklonalt antistoff mot nytt antigen knyttet til menneske-tumorer.
DE69228701D1 (de) Fragmente von Prion Proteinen.
TR200001253T2 (tr) Tümöre özel antijenler
PE20021151A1 (es) Uso de anticuerpos anti-tnf como farmacos en el tratamiento de trastornos septicos de racientes anemicos
DE69709632D1 (de) Humanisierte monoklonale anti-cd40 antikörper und fragmente zur hemmung der b-zellaktivierung
ATE402192T1 (de) Anti-ccr4 antikörper und fragmente davon
DK0540573T3 (da) Assay for frit- og kompleksbundet prostataspecifikt antigen (PSA)
ATE279442T1 (de) Humanisierte antikörper, die amyloid beta peptid sequestrieren
Sandberg et al. Complement utilization by guinea pig γ1 and γ2 immunoglobulins through the C3 activator system
EP0265500A4 (de) Antikörper gegen menschlichen progesteronrezeptor sowie diagnosematerial und -verfahren.
DE3888224D1 (de) Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung.
DE68921979D1 (de) Antikörper für die antilymphozyten-antikörpertherapie.
Fishkin et al. IgE multiple myeloma: a report of the third case
DE60029953D1 (de) Spezifische antikörper gegen humanes choriongonadotropin hormone und deren verwendung in therapie und diagnose
ES2072423T3 (es) Anticuerpo monoclonal e inmunoensayo para el factor beta xiia de coagulacion de la sangre.